Health-related quality of life in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nuclei
Health-related quality of life in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nuclei
复制标题
DOI：
10.1002/mds.10111
复制
发表时间：
2002-05-01
影响因子：
8.6
通讯作者：
Ostergaard, K
中科院分区：
文献类型：
--
作者：
Just, H;Ostergaard, K
帕金森病（PD）是一种进行性神经退行性疾病，目前尚未治愈。它影响患者生活的许多方面，其中只有一些可以通过现有的临床评级量表进行监测。在过去的十年中，有一个新的重点是使用健康相关的生活质量（HRQOL）的措施来描述患者对治疗的反应。我们描述了接受双侧丘脑底核（DBS）脑深部电刺激（DBS）治疗PD的受试者与未接受手术治疗的类似受试者组的患者报告HRQOL。一系列连续的晚期特发性PD患者（n = 11）接受了DBS治疗。将该手术治疗组与等待手术的类似患者组（n = 13）进行前瞻性比较。在T-0、T-3和T-6三个时间段评价了通过帕金森病问卷（PDQ-39）测量的自我报告HRQOL。手术组在术前（T-0）、术后3个月（T-3）、术后6个月（T-6）采用统一帕金森病评分销售（Unified Parkinson's Disease Rating Sale，简称CAFRS）进行评估。对于手术组，HRQOL、TRORS第II和第III部分、停药期持续时间和运动障碍从T-0到T-3和从T-0到T-6显著改善，但非手术组无改善。11例接受DBS治疗的患者中有10例报告术后6个月的总评分较低（表明HRQOL较好）。这项前瞻性对照研究的结果表明，接受DBS治疗的晚期特发性PD患者在术后3个月和6个月的HRQOL和临床结局方面获得了显著改善。(C)2002运动障碍协会。
Parkinson's disease (PD) is a progressive neurodegenerative disorder for which there is as yet no cure. It affects many aspects of patients' lives, only some of which can be monitored by available clinical rating scales. In the past decade, there has been a new emphasis on the use of health-related quality of life (HRQOL) measures to describe patient response to treatment. We describe patient-reported HRQOL in subjects who underwent bilateral deep brain stimulation (DBS) of the subthalamic nuclei (STN) for the treatment of PD, compared with a similar group of subjects who did not receive surgical treatment. A consecutive series of patients (n = 11) with advanced idiopathic PD were treated with DBS of the STN. This surgically treated group was compared prospectively with a similar group of patients (n = 13) awaiting surgery. Self-reported HRQOL, measured by the Parkinson's Disease Questionnaire (PDQ-39) was evaluated at three time periods T-0, T-3, and T-6. The surgery group was evaluated according to the Unified Parkinson's Disease Rating Sale (UPDRS) before (T-0), 3 (T-3), and 6 months (T-6) after surgery. HRQOL, UPDRS part II and III, duration of off periods, and dyskinesias improved significantly from T-0 to T-3 and from T-0 to T-6 for the surgery group but not for the nonsurgery group. Ten of the 11 patients treated with DBS of the STN reported a lower summary score (indicating better HRQOL) 6 months after surgery. The results of this prospective controlled study suggest that patients with advanced idiopathic PD treated with DBS of the STN obtain significant improvements in patient reported HRQOL and in clinical outcomes 3 and 6 months after surgery. (C) 2002 Movement Disorder Society.